Dana Taylor


Authored Items

Preventing Relapse in Myeloma Carries Economic Benefits, Reduces Overall Costs

March 2015, Vol 6, No 2 - Economics of Cancer Care

San Francisco, CA—In what is believed to be the first economic analysis of disease progression of patients with myeloma, researchers found that in patients with newly diagnosed myeloma, the monthly costs are reduced by 68% between the first 4 months through 18 months, but they then rise steeply when the disease relapses. The data were presented at the 2014 American Society of Hematology meeting. [ Read More ]

Olaparib-Carboplatin Combination Shows Promise for Patients with Ovarian or Triple-Negative Breast Cancer

May 2015, Vol 6, No 4 - AACR Meeting Highlights

Philadelphia, PA—The use of the poly (ADP-ribose) polymerase (PARP) inhibitor, olaparib (Lynparza), plus carboplatin chemotherapy shows promising activity in patients with recurrent breast or ovarian cancer; furthermore, the order of administration of these therapies did not affect the occurrence of side effects, according to new data from a phase 1 clinical trial presented at the 2015 American Association for Cancer Research (AACR) meeting. [ Read More ]

Assessing the Cost-Effectiveness of Necitumumab in Squamous-Cell Lung Cancer

August 2015, Vol 6, No 7 - Economics of Cancer Care

Chicago, IL—An economic analysis presented by Daniel Goldstein, MD, of Emory University, Atlanta, GA, at the 2015 American Society of Clinical Oncology meeting, was conducted to see at what price will necitum­umab (which is currently being reviewed by the FDA for use in metastatic squamous-cell lung cancer) be cost-­effective. According to this analysis, necitumumab will have to be priced at less than $1300 per cycle to be cost-­effective based on the accepted willing­ness-to-­pay threshold of $150,000. [ Read More ]

All-Oral Regimen May Become a New Standard of Care in Advanced Multiple Myeloma

February 2016, Vol 7, No 1 - Multiple Myeloma

With the recent FDA approval of the first oral proteasome inhibitor ixazomib (Ninlaro), patients with relapsed or refractory multiple myeloma who have received previous treatment now have access to an all-oral regimen. The FDA-indicated triplet regimen of ixazomib, lenalidomide (Revlimid), and dexamethasone (Decadron) significantly improved progression-free survival (PFS) compared with the doublet of lenalidomide and dexamethasone, reported Philippe Moreau, MD, University of Nantes, France, at ASH 2015. [ Read More ]